Cajal Therapeutics
Cajal Therapeutics is a Seattle biotechnology company developing iron-mobilizing medicines for anemias of inflammation, neurodegenerative disease, and other iron-related disorders.
Cajal Therapeutics advances a pipeline of iron-homeostasis therapies led by CTX001, a first-in-class iron mobilizer for anemias of inflammation, with first Phase 1 data expected in the second half of 2026. Additional programs CTX201 and CTX211 extend the iron-mobilizer franchise alongside central nervous system candidates.
The company pairs small-molecule iron mobilizers with RNA-based approaches, including an oligonucleotide alliance with Creyon Bio for neurodegenerative disease targets. Discovery-stage programs continue to feed the pipeline from its Seattle research base.
Cajal Therapeutics operates in large neurodegeneration and anemia-of-inflammation markets where iron dysregulation is increasingly recognized as a disease driver. Its pipeline spanning CTX001, CTX201, CTX211 and central nervous system programs positions it across chronic kidney disease anemia and neurodegenerative indications.
The Creyon Bio partnership announced in May 2024 opens oligonucleotide-based medicines as a second modality with IND-enabling programs underway. Continued investor support and platform expansion give Cajal room to advance multiple candidates toward clinical proof points.
Cajal Therapeutics differentiates through its iron-homeostasis platform, combining small-molecule iron mobilizers with RNA-based medicines for neurodegeneration and inflammatory anemias. Its human-genetics-driven target discovery and functional genomics give it multiple shots across CTX001, CTX201 and CTX211.
The May 2024 alliance with Creyon Bio adds engineered oligonucleotide capabilities with defined program responsibilities reaching IND-enabling stages. Backing from The Column Group, Lux Capital and Bristol Myers Squibb further validates the platform and extends development reach.
Cajal Therapeutics is a Seattle biotechnology company developing iron-mobilizing medicines for anemias of inflammation, neurodegenerative disease, and other iron-related disorders.